MXPA04011879A - Agente transformante de bacterias. - Google Patents

Agente transformante de bacterias.

Info

Publication number
MXPA04011879A
MXPA04011879A MXPA04011879A MXPA04011879A MXPA04011879A MX PA04011879 A MXPA04011879 A MX PA04011879A MX PA04011879 A MXPA04011879 A MX PA04011879A MX PA04011879 A MXPA04011879 A MX PA04011879A MX PA04011879 A MXPA04011879 A MX PA04011879A
Authority
MX
Mexico
Prior art keywords
bacterial strain
unsubstituted
substituted
agent
bacterial
Prior art date
Application number
MXPA04011879A
Other languages
English (en)
Spanish (es)
Inventor
Leslie Rowland Hill Robert
Original Assignee
Pharmaceutica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutica Ltd filed Critical Pharmaceutica Ltd
Publication of MXPA04011879A publication Critical patent/MXPA04011879A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MXPA04011879A 2002-05-31 2003-06-02 Agente transformante de bacterias. MXPA04011879A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212622.5A GB0212622D0 (en) 2002-05-31 2002-05-31 Bacterial transforming agent
PCT/GB2003/002402 WO2003101488A1 (en) 2002-05-31 2003-06-02 Bacterial transforming agent

Publications (1)

Publication Number Publication Date
MXPA04011879A true MXPA04011879A (es) 2005-09-12

Family

ID=9937806

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04011879A MXPA04011879A (es) 2002-05-31 2003-06-02 Agente transformante de bacterias.

Country Status (13)

Country Link
US (1) US20060040871A1 (https=)
EP (1) EP1553981A1 (https=)
JP (1) JP2006504404A (https=)
AU (1) AU2003232352A1 (https=)
BR (1) BR0311482A (https=)
CA (1) CA2487597A1 (https=)
EA (1) EA007093B1 (https=)
GB (1) GB0212622D0 (https=)
IL (1) IL165433A0 (https=)
MX (1) MXPA04011879A (https=)
NO (1) NO20045680L (https=)
NZ (1) NZ537447A (https=)
WO (1) WO2003101488A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036121A1 (en) * 2007-09-12 2009-03-19 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
AU2010313228B2 (en) * 2009-10-30 2014-05-29 Biogenic Innovations, Llc Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms
US9839609B2 (en) 2009-10-30 2017-12-12 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
DE102010013587A1 (de) * 2010-03-31 2011-10-06 Heliolux Gmbh N-(Aminoacyl)-Amino-Ester
WO2012106469A2 (en) * 2011-02-01 2012-08-09 New York University Methods for treating infections by targeting microbial h2s-producing enzymes
HRP20200101T1 (hr) 2014-11-06 2020-04-03 Xellia Pharmaceuticals Aps Glikopeptidni pripravci
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
WO2018237268A1 (en) * 2017-06-22 2018-12-27 Brown University Novel antibacterial compounds and methods of making and using same
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834430A (en) * 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains

Also Published As

Publication number Publication date
US20060040871A1 (en) 2006-02-23
NO20045680L (no) 2005-02-28
BR0311482A (pt) 2005-03-15
GB0212622D0 (en) 2002-07-10
EA007093B1 (ru) 2006-06-30
JP2006504404A (ja) 2006-02-09
EA200401589A1 (ru) 2005-06-30
CA2487597A1 (en) 2003-12-11
IL165433A0 (en) 2006-01-15
EP1553981A1 (en) 2005-07-20
WO2003101488A1 (en) 2003-12-11
NZ537447A (en) 2006-12-22
AU2003232352A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
MX2009010024A (es) Nuevo compuesto de adenina.
WO2008114819A1 (ja) 新規アデニン化合物
MX2010013275A (es) Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.
JO2282B1 (en) Oxazole derivatives
NO20070984L (no) Dihydropterididinon infusjonslosning som har en lang lagringstid
TW200642683A (en) Heterocyclic compound
EP1679309A4 (en) ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
GB2442148A (en) FK 228 derivates as HDAC inhibitors
MXPA04011879A (es) Agente transformante de bacterias.
NO20082630L (no) Vann-opploslige benzoazepinforbindelser og farmasoytisk forbindelse
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
WO2008005651A3 (en) Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
MX2009006467A (es) Profarmacos solubles en agua de cloranfenicol, tiamfenicol y analogos de los mismos.
NO20062255L (no) 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML)
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами
TR200102082T2 (tr) Spesifikasyon benzamit türevi ve bunu içeren ilaç
NO20053464L (no) Medikament mot kronisk smerte
Klee et al. Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif
DK1493441T3 (da) Terapeutisk middel for næringskompentenceforstyrrelse i maven
DE60021347D1 (de) Antibakteriell wirksame hydroxamsäure-derivate
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
MXPA05008190A (es) Derivado de oligosacarido.
MY121785A (en) Hydroxamic acid derivatives as inhibitors of the production of soluble cd23
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments